{"id":"NCT03434379","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","officialTitle":"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-15","primaryCompletion":"2020-08-31","completion":"2022-11-17","firstPosted":"2018-02-15","resultsPosted":"2021-11-05","lastUpdate":"2023-10-23"},"enrollment":558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"Atezolizumab + Bevacizumab","type":"EXPERIMENTAL"},{"label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.","primaryOutcome":{"measure":"Overall Survival (OS) in the Global Population","timeFrame":"From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)","effectByArm":[{"arm":"Sorafenib - Global","deltaMin":13.24,"sd":null},{"arm":"Atezolizumab + Bevacizumab - Global","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"},{"comp":"OG000 vs OG001","p":"0.0009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":25},"locations":{"siteCount":119,"countries":["United States","Australia","Canada","China","Czechia","France","Germany","Hong Kong","Italy","Japan","Poland","Russia","Singapore","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["36254201","36111952","34902530","34189869","34051880","33556230","32402160"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":156},"commonTop":["Hypertension","Diarrhoea","Proteinuria","Aspartate aminotransferase increased","Decreased appetite"]}}